255 related articles for article (PubMed ID: 35636978)
1. FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients.
Léger MA; Routy B; Juneau D
Semin Nucl Med; 2022 Nov; 52(6):707-719. PubMed ID: 35636978
[TBL] [Abstract][Full Text] [Related]
2. The Value of
Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
[TBL] [Abstract][Full Text] [Related]
3. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
4. Physiologic colonic uptake of
Cvetkovic L; Régis C; Richard C; Derosa L; Leblond A; Malo J; Messaoudene M; Desilets A; Belkaid W; Elkrief A; Routy B; Juneau D
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1550-1559. PubMed ID: 33128571
[TBL] [Abstract][Full Text] [Related]
5. Assessing the role of colonic and other anatomical sites uptake by [
Rizzo A; Cantale O; Mogavero A; Garetto L; Racca M; Venesio T; Anpalakhan S; Novello S; Gregorc V; Banna GL
Thorac Cancer; 2023 Aug; 14(24):2473-2483. PubMed ID: 37442801
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT.
Park S; Lee Y; Kim TS; Kim SK; Han JY
Medicine (Baltimore); 2020 Dec; 99(51):e23815. PubMed ID: 33371161
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT.
Dimitrakopoulou-Strauss A
Cancer Immunol Immunother; 2019 May; 68(5):813-822. PubMed ID: 30123922
[TBL] [Abstract][Full Text] [Related]
9. Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of
Castello A; Rossi S; Mazziotti E; Toschi L; Lopci E
J Nucl Med; 2020 Jun; 61(6):821-826. PubMed ID: 31862803
[TBL] [Abstract][Full Text] [Related]
10. Dual-Energy Computed Tomography-Based Iodine Quantitation for Response Evaluation of Lung Cancers to Chemoradiotherapy/Radiotherapy: A Comparison With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Based Positron Emission Tomography/Computed Tomography Response Evaluation Criterion in Solid Tumors.
Ren Y; Jiao Y; Ge W; Zhang L; Hua Y; Li C; Zhai W; Tang X; He W; Fang M; Zheng X
J Comput Assist Tomogr; 2018; 42(4):614-622. PubMed ID: 29613988
[TBL] [Abstract][Full Text] [Related]
11. Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors.
Mu W; Katsoulakis E; Whelan CJ; Gage KL; Schabath MB; Gillies RJ
Br J Cancer; 2021 Jul; 125(2):229-239. PubMed ID: 33828255
[TBL] [Abstract][Full Text] [Related]
12.
Nienhuis PH; Antunes IF; Glaudemans AWJM; Jalving M; Leung D; Noordzij W; Slart RHJA; de Vries EFJ; Hospers GAP
J Nucl Med; 2022 Jun; 63(6):899-905. PubMed ID: 34503964
[TBL] [Abstract][Full Text] [Related]
13. Interpretation of 2-[
Manson G; Lemchukwu AC; Mokrane FZ; Lopci E; Aide N; Vercellino L; Houot R; Dercle L
Eur Radiol; 2022 Sep; 32(9):6536-6544. PubMed ID: 35344061
[TBL] [Abstract][Full Text] [Related]
14. Impact of PET/CT for Assessing Response to Immunotherapy-A Clinical Perspective.
Lang D; Wahl G; Poier N; Graf S; Kiesl D; Lamprecht B; Gabriel M
J Clin Med; 2020 Oct; 9(11):. PubMed ID: 33126715
[TBL] [Abstract][Full Text] [Related]
15. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy.
Evangelista L; Cuppari L; Menis J; Bonanno L; Reccia P; Frega S; Pasello G
Nucl Med Commun; 2019 Aug; 40(8):802-807. PubMed ID: 31045745
[TBL] [Abstract][Full Text] [Related]
17. [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab.
Valentinuzzi D; Vrankar M; Boc N; Ahac V; Zupancic Z; Unk M; Skalic K; Zagar I; Studen A; Simoncic U; Eickhoff J; Jeraj R
Radiol Oncol; 2020 Jul; 54(3):285-294. PubMed ID: 32726293
[TBL] [Abstract][Full Text] [Related]
18. The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
Castello A; Toschi L; Rossi S; Mazziotti E; Lopci E
J Cancer Res Clin Oncol; 2020 May; 146(5):1235-1243. PubMed ID: 32048008
[TBL] [Abstract][Full Text] [Related]
19. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.
Seban RD; Mezquita L; Berenbaum A; Dercle L; Botticella A; Le Pechoux C; Caramella C; Deutsch E; Grimaldi S; Adam J; Ammari S; Planchard D; Leboulleux S; Besse B
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1147-1157. PubMed ID: 31754795
[TBL] [Abstract][Full Text] [Related]
20. Imaging assessment of toxicity related to immune checkpoint inhibitors.
Berz AM; Boughdad S; Vietti-Violi N; Digklia A; Dromain C; Dunet V; Duran R
Front Immunol; 2023; 14():1133207. PubMed ID: 36911692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]